high quality bpc 157 for gut recovery BPC-157 - Peptide Health & Tissue Repair BPC-157 Rapid Pro: Potential Benefits

This remains an emerging application and should be discussed carefully with your provider, but for patients who have plateaued with conventional rehabilitation, Synapse may offer an additional pathway

Content is for research and educational purposes only

Cell 157 , 882896 (2014)

BPC-157 has not completed the FDA approval process

In a 26-week Phase 2 obesity trial, cagrilintide 4.5mg produced a mean body-weight reduction of 10.8%, versus 3.0% on placebo and it outperformed liraglutide 3.0mg (10.8% vs 9.0%)[1]

This threshold was chosen to prioritize pathways with at least moderate evidence of a link to AD, ensuring that our network was focused on biologically relevant pathways while still being inclusive enough to capture a broad range of potential mechanisms